drug affinity complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
8 July An infantry battalion numbering 814 men from the US Army's 9th Infantry Division, the first of 25,000 American troops to be withdrawn from South Vietnam, arrived at McChord Air Force Base at 18:30 in a C-141 transport plane.
== Significance in carryover assessment == The pathological range of measurement could be of several order to reference interval(e.g., Sex hormone, Tumor marker, Troponin...etc.). A small portion of carryover could lead to erroneous results.
=== Discontinued === Amibegron (SR-58611; SR-58611A) – β3-adrenergic receptor agonist [26] BTG-1640 (ABIO-08/01; ABIO-0801) – undefined mechanism of action [27] Darigabat (CVL-865; PF-06372865; PF-6372865) – GABAA receptor positive allosteric modulator [28] Imagabalin (PD-0332334; PD-332334; PF-00195889) – α2δ subunit-containing voltage-gated calcium channel ligand [29] Naluzotan (PRX-00023) – serotonin 5-HT1A receptor agonist and sigma σ1 receptor agonist [30] Ocinaplon (CL-273547) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [31] Pagoclone (IP-456; Panex; RP-62955) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [32] PF-572778 – undefined mechanism of action [33] Rufinamide (Banzel; CGP-33101; E-2080; Inovelon; RUF-331; SYN-111) – sodium channel blocker and other actions [34] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [35] Tedatioxetine (Lu-AA24530) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), serotonin 5-HT2A, 5-HT2C, and 5-HT3 receptor antagonist, and α1A-adrenergic receptor antagonist [36]
Sources: en.wikipedia.org
== Published works == In 2013, Mendes published "Mendes System of Praying Exercises for the Hip Joints", through Kotarim International Publishing. In 2014, he published a new edition, "Mendes System Pain Free Arthritis Exercises", through Kotarim International Publishing. In 2019, Prof. Mendes published through Niv books a Hebrew edition "Who is Afraid of Medical Malpractice? Insights about Medicine and Law" He lights up the little-known world of medical malpractice and uses his experience to lay out five mental attitudes that cause doctors to make mistakes and lead them down a slippery slope. "Diary of Coronavirus family" a book published through Partridge Singapore April 2021 The Coronavirus family, a rowdy group of viruses who use the Human Beings as entertainment and cause them all sorts of trouble, gathers together and reminisces about the past, including various epidemics that they brought about over the course of history, up until the day that the Coronavirus pandemic broke out, leaving the Human Beings confused and helpless. The Coronavirus, whose name is CoV-2, describes how he caused the pandemic while also voicing some harsh criticism regarding the way the Human Beings chose to cope with it. Mama educates the virion, the youngster virus, about the tradition and life cycle of viruses, their genetics and how to grow to adulthood. Her beloved son Cov-2 is the virus involved in the break out of the COVID-19 in Wuhan, and he challenges himself to spread the epidemic to human beings worldwide.
Although a single injection of long-acting penicillin or other beta-lactam antibiotic cures the disease and is widely available, and the disease is highly localised, many eradication campaigns ended in complacency and neglect; even in areas where transmission was successfully interrupted, re-introduction from infected areas occurred. Yaws eradication remained a priority in South-East Asia. In 1995, the WHO estimated 460,000 worldwide cases. In the Philippines, yaws stopped being listed as a notifiable disease in 1973; as of 2020, it is still present in the country. India implemented a successful yaws eradication campaign that resulted in the 2016 certification by the WHO that India was free of yaws. In 1996 there were 3,571 yaws cases in India; in 1997 after a serious elimination effort began the number of cases fell to 735. By 2003, the number of cases was 46. The last clinical case in India was reported in 2003 and the last latent case in 2006; certification by the WHO was achieved in 2016. In 2012 the WHO officially targeted yaws for eradication by 2020 following the development of orally administered azithromycin as a treatment, but missed that target. The Morges approach (named after Morges, Switzerland, where a meeting on it was held) involved mass treatment with azithromycin. This was safe, but ran into problems with antibiotic resistance, and did not fully interrupt transmission.
Sales were legalized in Colorado in March 2015. On 25 March 2015, alcohol wholesalers and distributors in the state of Maryland announced an agreement to voluntarily ban the distribution and sale of powdered alcohol. Concerns included the potential for misuse by minors, the ease of using the powder to bring alcohol into public events or to spike drinks, and the potential to snort the powder. At the same time, a bill to ban Palcohol for one year was under consideration in the Maryland House of Delegates. In September 2015, the New Hampshire Liquor Commission banned the sale of Palcohol. By November 2015, most states had introduced legislation and laws to regulate or ban powdered alcohol. Twenty-seven have banned powdered alcohol, 2 more have placed temporary 1-year bans on the product and 3 have included powdered alcohol under their statutory definitions of alcohol meaning that it is covered by existing alcohol regulations.
===== MeSH D08.811.277.151 – aminohydrolases ===== MeSH D08.811.277.151.300 – gtp cyclohydrolase MeSH D08.811.277.151.350 – guanine deaminase MeSH D08.811.277.151.418 – methenyltetrahydrofolate cyclohydrolase MeSH D08.811.277.151.486 – nucleoside deaminases MeSH D08.811.277.151.486.075 – adenosine deaminase MeSH D08.811.277.151.486.250 – cytidine deaminase MeSH D08.811.277.151.486.625 – cytosine deaminase MeSH D08.811.277.151.653 – nucleotide deaminases MeSH D08.811.277.151.653.060 – amp deaminase MeSH D08.811.277.151.653.200 – dcmp deaminase
Sources: en.wikipedia.org
== Background == Gaines originally trained as a chemist and oceanographer, and received a master's degree from Scripps Institution of Oceanography in 1987. She has published peer-reviewed papers in The Journal of Organic Chemistry and the Journal of Chromatography A, as well as essays and short stories in an assortment of journals, literary magazines, and anthologies (Econ Papers, Nature, and The North American Review). She founded the "Fiction Meets Science" research and fellowship program at the University of Bremen.
For services to Justice and to Human Rights in Hong Kong. Emma Walters, Head of Department, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Lieutenant Colonel (Rtd) Christopher Warren, Secretary General, Royal Commonwealth Ex-Services League. For services to Commonwealth Veterans. Colin Whorlow, Team Leader, Foreign, Commonwealth and Development Office. For services to National Security.
Sequest (often stylized as SEQUEST) is a tandem mass spectrometry data analysis program used for protein identification. Sequest identifies collections of tandem mass spectra to peptide sequences that have been generated from databases of protein sequences.
It's impossible for us to accept such a plan." On 9 June 2022, the SAGO group, in development of its function of advisor to the WHO, published its first preliminary report. This report summarised existing findings and recommended that further studies be undertaken into possibly pathways of emergence.
Albinism Halo nevus Idiopathic guttate hypomelanosis (white sunspots) Piebaldism Pityriasis alba Postinflammatory hypopigmentation Primary adrenal insufficiency Progressive macular hypomelanosis Tinea versicolor Tuberculoid leprosy
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.